Introduction
============

According to statistics, bladder carcinoma is the seventh most common malignancy globally. Approximately 430,000 new cases are diagnosed annually, and \<165,000 cancer-related deaths occur each year.[@b1-ott-9-4917] Approximately 25% of the bladder cancers (BCs) are found to be muscle invasive (MIBC) nowadays. Patients with MIBC are at high risk of cancer-related death even after undergoing active treatment, with a 5-year survival proportion of 33% and 5.4% for local and distant metastatic MIBC, respectively.[@b2-ott-9-4917]

At present, cystoscopy and voided urine cytology remain the basic standard of BC diagnosis.[@b3-ott-9-4917] Although urine cytology has a high sensitivity in the detection of high-grade BC, it lacks sensitivity (ranging from 4% to 31%) to diagnose low-grade tumors. Cystoscopy is an invasive, expensive, painful, and potentially infectious procedure.[@b4-ott-9-4917] The development of new tools for the early diagnosis and discrimination of non-muscle-invasive BCs (NMIBCs) and MIBCs is a challenge in the field of uro-oncology, and it could provide benefit of invasiveness and help to take positive measures to reduce harm from malignant BCs. In addition, the accuracy of pathological diagnosis which was reduced by the limitation of specimen collection needs to be improved.[@b5-ott-9-4917]

Despite standard treatments for MIBC such as radical cystectomy (RC) and pelvic node dissection, 5-year overall survival rates have been shown to be between 26% and 77%.[@b6-ott-9-4917] One study revealed that trimodal treatment seems to lead to a better outcome in patients with MIBC compared with RC, and the median 5-year overall survival rate was 57% in the trimodal treatment group, when compared with 52%, 51%, and 53% in the whole group receiving RC or the group treated with RC alone or RC + chemotherapy, respectively.[@b7-ott-9-4917] Thus, an efficient early diagnostic approach is crucial to improve survival of BC patients. Many urothelial cell carcinoma (UCC) indicators such as microsatellite analysis, ImmunoCyt, NMP22, CYFRA21-1, Lewis-X, FISH, and hemoglobin (Hb) dipstick molecular tests and urine markers have been examined; however, due to the low sensitivity and specificity, they did not become a standard procedure for prognosis and diagnosis of patients with UCC.[@b8-ott-9-4917],[@b9-ott-9-4917] To date, many studies have revealed that neutrophil--lymphocyte ratio (NLR) would be associated with multiple types of cancers such as lung, breast, prostate, glioblastoma, colon, bladder, kidney, and pancreatic cancers.[@b10-ott-9-4917]--[@b17-ott-9-4917] Different types of studies have revealed that NLR could possibly be valuable in timely detection, informing prognoses, and monitoring treatment effects.

In addition, a number of studies suggest that an interactive relationship exists between hemostatic factors and tumor biology.[@b18-ott-9-4917]--[@b21-ott-9-4917] A number of procoagulant and fibrinolytic factors have been discovered to be overexpressed in tumors. One of these factors is plasma fibrinogen. Recent studies have revealed that elevated preoperative plasma fibrinogen levels are associated with worse outcome in various malignancies; however, the detecting value of plasma fibrinogen levels for bladder carcinoma has not yet been reported. In this study, we aimed to research if the integrated NLR and fibrinogen level has significance in discriminating between MIBC and NMIBC.

Methods
=======

We retrospectively evaluated the data of 669 patients with BC who underwent surgery and were monitored at the Second Hospital of Tianjin Medical University from 2010 to 2015. This study was approved by the Ethics Committee of The Second Hospital of Tianjin Medical University. All the patients signed an informed consent form to be included in this study. The tumors were graded according to the World Health Organization-International Society of Urologic Pathology 2004 guidelines and the TNM 2002 staging system. All of the pertinent laboratory and pathology results (tumor size and number, presence of carcinoma in situ, transurethral resection \[TUR\] and reoperation, postoperative immunotherapy, and chemotherapy), and medical data were obtained from the hospital databases.

Data obtained from the routine preoperative test results of the patients included the neutrophil and lymphocyte counts, NLR, levels of fibrinogen, Hb, red blood cells (RBCs), mean corpuscular Hb, mean corpuscular Hb concentration, creatinine, glucose, albumin total protein, and monocytes, and age. The NLR was determined by dividing the absolute neutrophil count by the absolute lymphocyte count. Patients were divided into two groups, NMIBC (group-I) and MIBC (group-II), according to their pathologies after the primary TUR and reoperation (including secondary TUR, RC, and partial resection of the bladder).

Statistical analyses were performed using IBM SPSS Statistics for Windows, version 20.0 (IBM Corporation, Armonk, NY, USA). For intergroup comparison, data obtained from NMIBC and MIBC groups were evaluated using independent samples *t*-test. The cutoff value of the NLR, fibrinogen level, and integrated NLR and fibrinogen level was determined with receiver operating characteristic (ROC) curve. *P*\<0.05 was accepted as statistically significant, and *P*\<0.01 as extremely significantly different.

Results
=======

According to the study results, group-I consisted of 579 patients, while group-II consisted of 90 patients. Mean age of patients in group-I and group-II was 65.21±11.9 and 67.46±11.4 years, respectively. The NLRs of group-I and group-II were found as 2.71±2.46 and 4.66±8.00, respectively (*P*\<0.001). The fibrinogen levels of group-I and group-II were found as 3.13±0.70 and 3.41±0.84 g/L, respectively (*P*=0.001). Data of group-I and group-II are summarized in [Table 1](#t1-ott-9-4917){ref-type="table"} (including the neutrophil and lymphocyte counts, NLR, levels of fibrinogen, Hb, RBCs, MCH, MCHC, creatinine, glucose, albumin total protein, and monocytes, and age). From [Table 1](#t1-ott-9-4917){ref-type="table"}, we can understand that mean of white blood cells, neutrophils, NLR, and fibrinogen was significantly higher in MIBC (*P*\<0.05), while that of monocytes, RBCs, Hb, and albumin was significantly higher in NMIBC (*P*\<0.05). Whether the NLR or fibrinogen level can distinguish between tumors in group-I and group-II was evaluated with ROC curve; the cutoff value was found as 2.01 for NLR and 3.17 g/L for fibrinogen level according to the Youden index ([Figure 1](#f1-ott-9-4917){ref-type="fig"}). For these values, sensitivity was determined as 67.1% and 58%, specificity as 52.7% and 58%, and area under the concentration--time curve (AUC) as 0.601 (*P*=0.031, confidence interval =0.547--0.653) and 0.60 (*P*=0.001, confidence interval =0.551--0.651), respectively. The cutoff value of integrated NLR and fibrinogen level was found as 0.166; hereby, the sensitivity was 86%, specificity was 42%, and AUC was 0.801 (*P*=0.01, confidence interval =0.763--0.838).

Discussion
==========

The development of new tools for the early diagnosis and prognosis of BC is a challenge in the field of urooncology. It is therefore feasible in clinical practice to assess malignancy of cancer with simple, inexpensive, and objective tools. The aim of our study was to assess whether the NLR or fibrinogen level would be useful in predicting disease severity in BC patients. Our finding may help urologists in counseling patients about their risk of upstaged disease and make an adminicular decision on whether to perform early cystectomy or neoadjuvant treatment. Raj et al proved that neoadjuvant chemotherapy improved survival times of T2 BC patients who underwent RC. This benefit was more obviously seen in those with extravesical, advanced malignant neoplasms.[@b22-ott-9-4917]

Inflammatory and immune cells are the basic constituents of the tumor microenvironment. Inflammation might frequently be associated with different stages of tumor development, including initiation, promotion, malignant conversion, invasion, and metastasis.[@b23-ott-9-4917] Several articles have revealed the prognostic value of various inflammatory factors such as albumin, C-reactive protein, Glasgow prognostic score, and prognostic index in cancer patients. The NLR represents an easily measured, reproducible, and inexpensive marker of systemic inflammation which has been confirmed to be associated with oncologic outcomes in multiple malignancies, including breast, colorectal, lung, and gastric cancers. Gondo et al stated that NLR threshold value \<2.5 and ≥2.5 was an independent prognostic factor; additionally, tumor size, hydronephrosis, Hb levels, and the combination of these factors could stratify disease-specific survival risks in BC patients undergoing RC.[@b24-ott-9-4917] Azuma et al revealed that preoperative NLR was intensively related to a poor prognosis in patients with upper urinary tract UCC as an indication of pathologic T stage and tumor grade. In their study, it was shown that NLR ≥2.5 could predict local tumor aggressiveness and independently forecast the local pathologic situation, and NLR was obviously associated with recurrence-free survival and cancer-specific survival rates.[@b25-ott-9-4917] Ozyalvacli et al reported that the best cutoff value of the NLR as an indicator of recurrence and progression in BC patients was ≥2.43; patients with an NLR above this value experienced significantly higher recurrence without progression, highlighting the potential role of the NLR in pT1 superficial bladder tumors.[@b26-ott-9-4917] Moreover, Ceylan et al reported that the cutoff value was found as 3.96 through the Youden index; for this value, sensitivity was calculated as 50%, specificity as 22.8%, and AUC as 0.615.[@b27-ott-9-4917] Reportedly, patients who were upstaged to ≥pT3 demonstrated statistically greater NLRs compared with patients who stayed at ≤pT2 stage.[@b28-ott-9-4917] Other studies have revealed that this result may be useful in prognosis for BC patients.[@b15-ott-9-4917],[@b29-ott-9-4917]--[@b33-ott-9-4917]

Fibrinogen is synthesized in the liver as a 350 kDa glycoprotein and converted to insoluble fibrin by activated thrombin. Fibrinogen plays a part in blood coagulation, thrombosis, wound healing, and platelet aggregation. Recently, much attention was attracted to the relationship between hypercoagulation and the progression of malignancies. Moreover, recent studies suggest that fibrinogen is associated with tumor evolution including ovarian,[@b34-ott-9-4917] breast,[@b35-ott-9-4917] non-metastatic renal cell,[@b36-ott-9-4917] cervical,[@b37-ott-9-4917] endometrial,[@b38-ott-9-4917] esophageal,[@b39-ott-9-4917] colon,[@b40-ott-9-4917] prostate,[@b41-ott-9-4917] endometrial,[@b42-ott-9-4917] non-small-cell lung,[@b43-ott-9-4917] and rectal cancers.[@b44-ott-9-4917] According to our knowledge, this is the only study evaluating the relationship between BC and fibrinogen in literature. Also, the fibrinogen was unknown to be an independent prognostic factor in predicting survival.

ROC curve analysis was performed to assess the ability of the integrated NLR and fibrinogen level to discriminate between NMIBC and MIBC in the validation. The cutoff value of integrated NLR and fibrinogen value was estimated according to the Youden index. With this value, sensitivity was found as 86%, specificity was 42%, and AUC was 0.801 (*P*=0.01, confidence interval =0.763--0.838). Compared to NLR or fibrinogen level alone, we found that the integrated NLR and fibrinogen level had high sensitivity, though the specificity was less. It could help the urologists make better decision on treatment option for patients according to the hematological indexes combined with patient individual preferences and needs.

Limitations
===========

Some limitations of the present study must be mentioned. First, the information involved in this study were obtained from 669 patients, and the study was conducted in a single center with a small sample; hence, the results cannot be generalized. Including surgeon and pathologist in the study was also a limitation that the proportion of NMIBC and MIBC patients did not correspond to the international epidemiological data. Due to the retrospective nature of this study, the attributable factors suffered from a recall bias and were not analyzable. Second, the role of NLR and fibrinogen level in the cell carcinoma was not investigated in this study.

Conclusion
==========

In conclusion, immune markers such as NLR and hemostatic factor fibrinogen may assist in distinguishing patients following surgery for a malignant indication. In the current study, we demonstrated that an elevated preoperative NLR and fibrinogen level was associated with long-term progression. Integrated NLR and fibrinogen level may therefore serve as an easily obtained preoperative factor to help determine MIBC and NMIBC of patients following surgery for BCs.
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**Notes:** According to the cutoff value of NLR, sensitivity was found as 67.1%, specificity was 52.7%, and AUC was 0.601 (*P*=0.031, confidence interval =0.547--0.653). According to the cutoff value of fibrinogen, sensitivity was found as 58%, specificity was 58%, and AUC was 0.60 (*P*=0.001, confidence interval =0.551--0.651). According to the cutoff value of integrated NLR and fibrinogen level, sensitivity was found as 86%, specificity was 42%, and AUC was 0.801 (*P*=0.01, confidence interval =0.763--0.838).\
**Abbreviations:** NLR, neutrophil--lymphocyte ratio; AUC, area under the ROC curve; ROC, receiver operating characteristic.](ott-9-4917Fig1){#f1-ott-9-4917}

###### 

The demographics, risk factors, and clinicopathological characteristics of the two groups of patients

  Parameters              NMIBC (579), mean ± SD   MIBC (90), mean ± SD   *P*-value
  ----------------------- ------------------------ ---------------------- -----------
  Age (years)             65.20±11.95              67±11.40               0.093
  WBCs (10^9^/L)          6.63±2.24                8.11±7.72              0.000
  Neutrophils (10^9^/L)   4.21±2.24                5.76±7.68              0.000
  Lymphocytes (10^9^/L)   2.12±6.38                1.72±0.72              0.553
  NLR                     2.71±2.46                4.66±8.00              0.00
  Monocytes (10^8^/L)     6.15±1.75                5.74±2.02              0.047
  RBCs (10^12^ g/L)       4.51±0.54                4.27±0.62              0.00
  Hb (g/L)                140.49±18.06             132.45±20.25           0.000
  MCH (pg)                31.28±2.05               30.98±1.77             0.194
  MCHC (g/L)              339.09±8.78              338.20±8.79            0.368
  Creatinine (μmol/L)     80.16±40.76              80.06±29.80            0.983
  Glucose (mmol/L)        5.62±1.57                5.93±1.73              0.105
  Fibrinogen (g/L)        3.13±0.70                3.41±0.84              0.001
  Albumin (g/L)           41.60±5.22               39.97±5.69             0.008
  Total protein (g/L)     66.07±6.53               65.44±6.84             0.412

**Note:** For intergroup comparison, data obtained from NMIBC and MIBC groups were evaluated using independent samples *t*-test.

**Abbreviations:** NMIBC, non-muscle-invasive bladder cancer; SD, standard deviation; MIBC, muscle-invasive bladder cancer; WBCs, white blood cells; NLR, neutrophil--lymphocyte ratio; RBCs, red blood cells; Hb, hemoglobin; MCH, mean corpuscular Hb; MCHC, mean corpuscular Hb concentration.
